Updated corporate overview
10/06/2019 – AB Science is providing an updated coporate overview of the Company
Summary of the webconference held on June 5, 2019
05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019
June 5 2019 web conference presentation
05/06/2019 – AB Science web conference – Part 2
Summary of the webconference held on June 4, 2019
04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019
June 4 2019 web conference presentation
04/06/2019 – AB Science web conference presentation (Part 1)
Web conference on June 4 and 5, 2019
30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
Lifting of the ANSM clinical hold
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
Annual financial results as of 31 December, 2018
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.